Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
chemotherapy
|
| gptkbp:approvalYear |
2004
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XC07
|
| gptkbp:biosimilar |
yes
|
| gptkbp:blackBoxWarning |
yes
|
| gptkbp:CASNumber |
216974-75-3
|
| gptkbp:contraindication |
hypersensitivity to bevacizumab
|
| gptkbp:developedBy |
gptkb:Genentech
|
| gptkbp:genericName |
gptkb:bevacizumab
|
| gptkbp:hasMolecularFormula |
C6638H10160N1720O2104S44
|
| https://www.w3.org/2000/01/rdf-schema#label |
Avastin
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
VEGF inhibitor
|
| gptkbp:monoclonalAntibodyType |
humanized
|
| gptkbp:patentExpired |
2019
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:PubChem_CID |
DB00112
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
bleeding
hypertension proteinuria gastrointestinal perforation |
| gptkbp:UNII |
82F0S815PN
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
gptkb:cancer gptkb:glioblastoma colorectal cancer renal cell carcinoma |
| gptkbp:bfsParent |
gptkb:Genentech
gptkb:Lucentis |
| gptkbp:bfsLayer |
5
|